id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308184-w8ewm8ve	Sarzi-Puttini, Piercarlo	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion	2020-05-05		.txt	text/plain	3430	143	40	Disease activity, co-morbidities, immunosuppressive drugs including glucocorticoids (GCs), disease-modifying antirheumatic drugs (DMARDs), conventional synthetic (csDMARDs), biological (bDMARDs), targeted synthetic DMARDs (tsDMARDs), and the biological agents currently available for treating patients with IBD are all considered risk factors for infective complications. This has raised concerns about the potential risk of COVID-19 infection in IBD patients (particularly those who are taking immunosuppressants or biological drugs) because of the high morbidity and mortality rates observed in the old and frail with co-morbidities. As a result of the early warning and strict preventive measures, none of the patients developed any significant clinical manifestation of COVID-19 infection, not even those being treated with corticosteroids (12.6%), immunosuppressants (11%) and biological agents (6%), or those with co-morbidities. The first challenge for rheumatologists is to decide whether to interrupt or continue a treatment: although it is true that the treatment is designed to control disease activity, it is also undeniable that the same treatment may expose patients, such other infection, to an increased risk for COVID-19.	./cache/cord-308184-w8ewm8ve.txt	./txt/cord-308184-w8ewm8ve.txt